文献速递膀胱癌与上尿路尿路上皮癌

国际膀胱癌组提出的中危非肌层浸润性膀胱癌评分系统及亚分层模型的临床验证:多中心青年学术泌尿肿瘤学家尿路上皮工作组协作研究

Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration.
PubMed 文献 · Eur Urol Oncol · 2024-06-20

本研究为国际多中心回顾性研究,纳入2012至2022年接受经尿道膀胱肿瘤电切术及辅助膀胱内化疗的677例中危非肌层浸润性膀胱癌患者,按风险因素数目分为IR-low、IR-intermediate和IR-high三组,评估1年和3年无复发生存率与无进展生存率,结果示三组间RFS和PFS率存在显著差异。

要点

  • 677例中危NMIBC中,IR-low组231例(34%),IR-intermediate组364例(54%),IR-high组82例(12%)。
  • IR-low、IR-intermediate与IR-high三组间的无复发生存率(RFS)和无进展生存率(PFS)存在显著差异。
  • 本研究首次对IBCG评分系统及中危NMIBC亚分层模型进行临床验证,结果支持其在临床实践中使用。

核心结论

  • 本研究首次对IBCG评分系统及中危NMIBC亚分层模型进行临床验证,结果表明中危NMIBC患者可根据复发和进展风险被正确分为三个不同亚组,结果支持该评分系统在临床实践中使用。

研究设计与样本

  • 国际多中心回顾性研究,纳入2012年至2022年诊断为IR NMIBC并接受经尿道膀胱肿瘤电切术及辅助膀胱内化疗的患者677例,按风险因素有无分为IR-low(无风险因素)、IR-intermediate(1-2个风险因素)和IR-high(≥3个风险因素)三组。

主要发现

  • 677例IR NMIBC患者中,IR-low组231例(34%),IR-intermediate组364例(54%),IR-high组82例(12%)。
  • IR-low、IR-intermediate和IR-high三组间的无复发生存率(RFS)和无进展生存率(PFS)存在显著差异。

临床怎么用

  • 作者结论认为结果支持该评分系统在临床实践中使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) encompasses a broad spectrum of disease, with heterogeneous outcomes in terms of disease recurrence and progression. The International Bladder Cancer Group (IBCG) recently proposed an updated scoring model for IR substratification that is based on five key risk factors. Our aim was to provide a clinical validation of the IBCG scoring system and substratification model for IR NMIBC. METHODS: This was an international multicenter retrospective study. Patients diagnosed with IR NMIBC between 2012 and 2022 and treated with transurethral resection of the bladder and adjuvant intravesical chemotherapy were included. According to the presence or absence of risk factors, patients with IR NMIBC were further categorized in IR-low (no risk factors), IR-intermediate (1-2 risk factors), and IR-high (≥3 risk factors) groups. The 1-yr and 3-yr rates for recurrence-free survival (RFS) and progression-free survival (PFS) were evaluated for each subgroup. Cox regression analyses were used to compare oncological outcomes between the groups. KEY FINDINGS AND LIMITATIONS: Of the 677 patients with IR NMIBC included in the study, 231 (34%), 364 (54%), and 82 (12%) were categorized in the IR-low, IR-intermediate, and IR-high groups, respectively. There were significant differences in RFS and PFS rates between these groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: We provide the first clinical validation of the IBCG scoring system and model for substratification of IR NMIBC. PATIENT SUMMARY: Our study demonstrates that patients with intermediate-risk non-muscle-invasive bladder cancer can be correctly classified into three distinct subgroups according to their risk of both disease recurrence and progression. Our results support use of this scoring system in clinical practice.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Soria F, Rosazza M, Livoti S, et al. Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration. Eur Urol Oncol. 2024. PMID: 38906794. doi:10.1016/j.euo.2024.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。